Key result
Rosuvastatin 40 mg reduces CIMT progression versus placebo over 24 months.
Why the study?
Does rosuvastatin 40 mg reduce the progression of carotid intima media thickness in low risk subjects?
Population
984 low risk subjects
Comparison
Rosuvastatin 40 mg vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
up to 2 years
Authors
Loading...
Statin CIMT benefit emerges by 12 months; confirms early divergence timing seen in prior event-driven statin trials.
RCT (n=984)
Double-blind
randomized
Does rosuvastatin 40 mg reduce the progression of carotid intima media thickness in low risk subjects?
Absolute Event Rate: -0.0014% vs 0.0131%
p-value: p=<0.001
Intensive lipid lowering with rosuvastatin 40 mg significantly reduces the progression of carotid atherosclerosis within 12 months of treatment in low-risk subjects.
Bots et al. (2009) conducted an RCT in Atherosclerosis (n=984). Rosuvastatin vs. Placebo was evaluated on Rate of change of carotid intima media thickness (CIMT) at 24 months (p=<0.001). Rosuvastatin 40 mg significantly reduced the rate of carotid intima media thickness progression compared to placebo after 24 months (-0.0014 vs 0.0131 mm/year; P<0.001).